Cargando…
D,L-Lysine-Acetylsalicylate + Glycine (LASAG) Reduces SARS-CoV-2 Replication and Shows an Additive Effect with Remdesivir
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease-19 (COVID-19) is still challenging healthcare systems and societies worldwide. While vaccines are available, therapeutic strategies are developing and need to be adapted to each patient. Many clinical ap...
Autores principales: | Jungwirth, Johannes, Häring, Clio, König, Sarah, Giebeler, Liane, Doshi, Heena, Brandt, Christian, Deinhardt-Emmer, Stefanie, Löffler, Bettina, Ehrhardt, Christina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266999/ https://www.ncbi.nlm.nih.gov/pubmed/35805887 http://dx.doi.org/10.3390/ijms23136880 |
Ejemplares similares
-
The influenza replication blocking inhibitor LASAG does not sensitize human epithelial cells for bacterial infections
por: Wilden, Janine J., et al.
Publicado: (2020) -
SARS-CoV-2 Causes Severe Epithelial Inflammation and Barrier Dysfunction
por: Deinhardt-Emmer, Stefanie, et al.
Publicado: (2021) -
The Local Anaesthetic Procaine Prodrugs ProcCluster(®) and Procaine Hydrochloride Impair SARS-CoV-2 Replication and Egress In Vitro
por: Häring, Clio, et al.
Publicado: (2023) -
Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice
por: Deinhardt-Emmer, Stefanie, et al.
Publicado: (2021) -
Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients
por: Scheuch, Gerhard, et al.
Publicado: (2018)